You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Vigabatrin, tiagabine, and visual fields
  1. MC Lawden
  1. Department of Neurology, Leicester Royal Infirmary, Leicester LE1 5WW, UK; lawden01@globalnet.co.uk

    https://doi.org/10.1136/jnnp.74.3.286

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      A retinotoxic class effect of GABAergic antiepileptic drugs seems unlikely

      The paper by Krauss et al (this issue, pp 339–343)1 helps to settle a controversy that has been simmering in the epilepsy world for several years.1 Initial reports that vigabatrin use was associated with irreversible visual field defects evoked scepticism. Various voices held that such visual field defects were not uncommon in patients with epilepsy and might be associated with epilepsy itself rather than from specific drug treatment. Evidence has now accumulated to convince all but the most sceptical that the antiepileptic drug vigabatrin, an irreversible inhibitor of GABA transaminase, has a strong tendency to produce visual field constriction by a …

      View Full Text

      Linked Articles